Roche Buys Spinal Muscular Atrophy Pipeline

Swiss pharmaceutical giant Roche makes a large investment in the neurodegenerative disease space with its $490 million acquisition of exclusive rights to NJ-based PTC Therapeutics’ program for spinal muscular atrophy (SMA). The arrangement gives Roche global rights to three preclinical compounds in PTC’s SMA pipeline, which were developed in collaboration with the SMA Foundation.

Click here to read more.

Share this: